| Business Type | Exporter, Supplier, Retailer |
| Dosage | 200 Mg |
| Application | Treatment Of Adult Patients With Hormone Receptor-positive,HER2-negative,Locally Advanced Or Metastatic Breast Cancer With Specific Alterations |
| Packaging | Box |
| Click to view more | |
Product Details
Storage
Store At Room Temperature
Type
Tablets
Packaging Size
64 Tablets In One Box
Form
Tablet
Indication
Combination With Fulvestrant For Specified Breast Cancer Treatment
Route Of Administration
Oral
LuciCapiva is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Looking for "Lucicapiva Capivasertib Tablets200 Mg" ?
Pack
